WO2005016323A3 - Use of c-kit inhibitors for treating type ii diabetes - Google Patents

Use of c-kit inhibitors for treating type ii diabetes Download PDF

Info

Publication number
WO2005016323A3
WO2005016323A3 PCT/IB2004/002934 IB2004002934W WO2005016323A3 WO 2005016323 A3 WO2005016323 A3 WO 2005016323A3 IB 2004002934 W IB2004002934 W IB 2004002934W WO 2005016323 A3 WO2005016323 A3 WO 2005016323A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
treating type
kit inhibitors
inhibitors
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/002934
Other languages
French (fr)
Other versions
WO2005016323A2 (en
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Priority to DE602004013792T priority Critical patent/DE602004013792D1/en
Priority to JP2006523710A priority patent/JP2007502809A/en
Priority to EP04769332A priority patent/EP1653934B1/en
Priority to US10/567,557 priority patent/US20070032521A1/en
Priority to CA002535242A priority patent/CA2535242A1/en
Publication of WO2005016323A2 publication Critical patent/WO2005016323A2/en
Publication of WO2005016323A3 publication Critical patent/WO2005016323A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method for treating type II diabetes, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from non-toxic, selective and potent c-kit inhibitors.
PCT/IB2004/002934 2003-08-15 2004-08-16 Use of c-kit inhibitors for treating type ii diabetes Ceased WO2005016323A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE602004013792T DE602004013792D1 (en) 2003-08-15 2004-08-16 USE OF C-KIT INHIBITORS FOR THE TREATMENT OF TYPE-2 DIABETES
JP2006523710A JP2007502809A (en) 2003-08-15 2004-08-16 Methods of using c-kit inhibitors for treating type II diabetes
EP04769332A EP1653934B1 (en) 2003-08-15 2004-08-16 Use of c-kit inhibitors for treating type ii diabetes
US10/567,557 US20070032521A1 (en) 2003-08-15 2004-08-16 Use of c-kit inhibitors for treating type II diabetes
CA002535242A CA2535242A1 (en) 2003-08-15 2004-08-16 Use of c-kit inhibitors for treating type ii diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49508803P 2003-08-15 2003-08-15
US60/495,088 2003-08-15

Publications (2)

Publication Number Publication Date
WO2005016323A2 WO2005016323A2 (en) 2005-02-24
WO2005016323A3 true WO2005016323A3 (en) 2005-04-07

Family

ID=34193274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002934 Ceased WO2005016323A2 (en) 2003-08-15 2004-08-16 Use of c-kit inhibitors for treating type ii diabetes

Country Status (7)

Country Link
US (1) US20070032521A1 (en)
EP (1) EP1653934B1 (en)
JP (1) JP2007502809A (en)
AT (1) ATE395052T1 (en)
CA (1) CA2535242A1 (en)
DE (1) DE602004013792D1 (en)
WO (1) WO2005016323A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
ATE508747T1 (en) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-KIT KINASE INHIBITORS
SI1664016T1 (en) 2003-09-22 2009-04-30 Euro Celtique Sa Therapeutic agents useful for treating pain
PL1664041T3 (en) 2003-09-22 2008-12-31 Euro Celtique Sa Phenyl-carboxamide compounds useful for treating pain
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
BRPI0418074B8 (en) * 2003-12-25 2021-05-25 Nippon Shinyaku Co Ltd amide derivative, pharmaceutical composition, bcr-abl tyrosine kinase inhibitor and therapeutic agents
ATE428421T1 (en) * 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
WO2007015569A1 (en) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
CA2620594C (en) * 2005-09-01 2012-08-21 Eisai R&D Management Co., Ltd. Pharmaceutical composition having improved disintegratability
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Anti-tumor agent for multiple myeloma
DE102005062986A1 (en) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituted propiolic acid amides and their use for the preparation of medicaments
CN104706637A (en) * 2006-05-18 2015-06-17 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
JPWO2008001956A1 (en) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 Liver fibrosis treatment
WO2008026748A1 (en) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
CA2663857C (en) 2006-09-20 2017-10-31 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
CA2676796C (en) * 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
MX2009012613A (en) 2007-05-22 2010-04-21 Achillion Pharmaceuticals Inc Heteroaryl substituted thiazoles and their use as antiviral agents.
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
PL2244737T3 (en) 2008-01-22 2020-05-18 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
KR101506062B1 (en) * 2008-01-29 2015-03-25 에자이 알앤드디 매니지먼트 가부시키가이샤 Combined use of angiogenesis inhibitor and taxane
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
CN102958523B (en) 2010-06-25 2014-11-19 卫材R&D管理有限公司 Use of combined antineoplastic agents with kinase inhibitory effects
CN103402519B (en) 2011-04-18 2015-11-25 卫材R&D管理有限公司 Therapeutic agent for tumor
JP6038128B2 (en) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (en) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd HIGHLY PURE QUINOLINE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF
LT3263106T (en) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES
KR102662228B1 (en) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 Combination of PD-1 antagonists and VEGFR/FGFR/RET tyrosine kinase inhibitors to treat cancer
MX373231B (en) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd ANTICANCER AGENT.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (en) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. TREATMENT OF HEPATOCELLULAR CARCINOMA
WO2022036104A1 (en) * 2020-08-12 2022-02-17 University Of Iowa Research Foundation Insulin sensitizers for the treatment of diabetes mellitus
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934931A2 (en) * 1995-06-07 1999-08-11 Sugen, Inc. 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators
WO2001064200A2 (en) * 2000-03-03 2001-09-07 Novartis Ag Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
WO2004014903A1 (en) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004076693A1 (en) * 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2004105763A2 (en) * 2003-05-27 2004-12-09 Haegerkvist Robert Per Use of tyrosine kinase inhibitor to treat diabetes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934931A2 (en) * 1995-06-07 1999-08-11 Sugen, Inc. 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators
WO2001064200A2 (en) * 2000-03-03 2001-09-07 Novartis Ag Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
WO2004014903A1 (en) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
WO2004076693A1 (en) * 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
WO2004098612A2 (en) * 2003-05-07 2004-11-18 Ab Science Calcitriol analogs of uses thereof
WO2004105763A2 (en) * 2003-05-27 2004-12-09 Haegerkvist Robert Per Use of tyrosine kinase inhibitor to treat diabetes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MA Y ET AL: "INDOLINONE DERIVATIVES INHIBIT CONSTITUTIVELY ACTIVATED KIT MUTANTS AND KILL NEOPLASTIC MAST CELLS", JOURNAL OF INVESTIGATIVE DERMATOLOGY, NEW YORK, NY, US, vol. 114, no. 2, February 2001 (2001-02-01), pages 392 - 394, XP001127437, ISSN: 0022-202X *
ZERMATI Y ET AL: "Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c - kit receptors found i mast cell neoplasms", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 22, 2003, pages 660 - 664, XP002286458, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
EP1653934A2 (en) 2006-05-10
EP1653934B1 (en) 2008-05-14
CA2535242A1 (en) 2005-02-24
JP2007502809A (en) 2007-02-15
DE602004013792D1 (en) 2008-06-26
US20070032521A1 (en) 2007-02-08
ATE395052T1 (en) 2008-05-15
WO2005016323A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2005016323A3 (en) Use of c-kit inhibitors for treating type ii diabetes
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
WO2004062613A3 (en) Hiv integrase inhibitors
WO2003024386A8 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
AU2005302085A1 (en) Copper containing materials for treating wounds, burns and other skin conditions
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2005030129A3 (en) Quinoline potassium channel inhibitors
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2005115304A3 (en) Use of c-kit inhibitors for treating fibrodysplasia
WO2003004006A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2005000192A3 (en) Glycogen synthase kinase-3 inhibitors
WO2004041794A8 (en) Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
WO2005016249A3 (en) Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
WO2005102346A3 (en) Use of c-kit inhibitors for treating fibrosis
WO2002098850A3 (en) Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
WO2003101382A3 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
PL371784A1 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
WO2003072106A3 (en) Use of tyrosine kinase inhibitors for treating substance use disorders
WO2005030792A3 (en) Quinoline potassium channel inhibitors
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2005018569A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2535242

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004769332

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006523710

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004769332

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007032521

Country of ref document: US

Ref document number: 10567557

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10567557

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004769332

Country of ref document: EP